Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Fig. 3

Combination HDAC inhibitors with MEK inhibitors enhance cell apoptosis in pancreatic cancer cells. a AsPC-1 cells were treated by MPT0E028 plus PD98059 (left panel) or SAHA plus PD98059 (right panel) with indicated concentrations for 72 h. sub-G1 cells were detected by flow cytometry and calculated by CellQuest software. AsPC-1 (b) and PANC-1 (c) cells were treated by DMSO, MPT0E028, MPT0E028 plus PD98059 (PD) or SAHA, and SAHA plus PD98059 with indicated concentrations for 72 h. AsPC-1 or BxPC-3 (d) cells were treated by DMSO, MPT0E028, and MPT0E028 plus trametinib (Tra) with indicated concentrations for 72 h. The protein level of cleaved caspase-3, PARP, H3K9ac, and actin were determined by western blotting. Actin was used as an internal control. e AsPC-1 cells were treated with DMSO, 2 μM MPT0E028 (E2), 20 μM PD98059 (PD20), and MPT0E028 plus PD98059 (E2PD20) for 24, 48, and 72 h. The fold change of cleaved caspase-3 was assessed by cleaved caspase-3 ELISA kit

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us